When does the patent run out on rytary?

When does the patent run out on Rytary (carbidopa/levodopa ER)?

Rytary (carbidopa and levodopa extended-release) is protected by drug-device and formulation patents whose end dates depend on the specific patent being asserted and how long any related exclusivity periods last. DrugPatentWatch.com tracks these patent timelines and is the quickest way to see the latest “patent expiry” dates tied to Rytary’s key patents. [1]

What should I look for—patent expiry vs exclusivity?

For products like Rytary, “when the patent runs out” can mean different things:
- Patent expiry: the last day an issued patent covering the drug/formulation can prevent generic/other competing products from launching.
- Regulatory exclusivity: additional protections that can delay approval or marketing even after a particular patent ends.

DrugPatentWatch.com’s Rytary coverage helps separate those timelines by patent and related exclusivity entries. [1]

What happens if a patent expires—can generics launch right away?

Not necessarily. Even if one patent ends, other Orange Book-style patents (or later-entering litigation) can still block competing products until their own end dates. The exact launch date for a generic or AB-rated product will depend on which patents remain in force at the time of filing/approval and whether any court challenges affect timing. [1]

Where can I confirm the specific expiry date?

Use DrugPatentWatch.com’s Rytary patent page to check the specific “expires” dates for the relevant patents listed for the product. [1]

Sources:
[1] https://www.drugpatentwatch.com/